Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Trial Profile

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Prasugrel
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Status changed from active, no longer recruiting to completed according to results published in the Journal of the American College of Cardiology.
    • 01 Nov 2016 Primary endpoint of changes in brachial artery flow mediated dilation has been met, according to results published in the Journal of the American College of Cardiology.
    • 01 Nov 2016 Primary endpoint of changes in circulating number of endothelial progenitor cells has been met, according to results published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top